Verastem Oncology doses first patient in Target-D 202 phase 2 registration-directed trial of versus-7375 for KRAS G12D-mutated advanced non-small cell lung cancer

VSTM•2026-07-22

First patient dosed in phase 2 trial

Verastem Inc. said Verastem Oncology has dosed the first patient in the Target-D 202 phase 2 registration-directed trial of versus-7375 for KRAS G12D-mutated advanced non-small cell lung cancer.

July 22 (Reuters) - Verastem Inc VSTM.O:
Verastem Oncology doses first patient in Target-D 202 phase 2 registration-directed trial of versus-7375 for KRAS G12D-mutated advanced non-small cell lung cancer.

Verastem Oncology doses first patient in Target-D 202 phase 2 registration-directed trial of versus-7375 for KRAS G12D-mutated advanced non-small cell lung cancer

First patient dosed in phase 2 trial

Related News

Crown Castle raises annual site rental revenue forecast on strong data demand

Magnolia Oil & Gas Operating Announces Pricing Of Offering Of $500 Million Senior Notes

Brookfield To Acquire Aypa Power

Century Communities investor deck spotlights affordable-home focus, land-light strategy

Southwest Airlines Expects 64 Boeing 737-8 Aircraft Deliveries